US Patent 7019193 Treatments using transgenic goat produced antithrombin III
Patent 7019193 was granted and assigned to GTC BIOTHERAPEUTICS, INC. on March, 2006 by the United States Patent and Trademark Office.
All edits
Edits on 17 Nov, 2023
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+541 characters)
Article
Patent abstract
This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Edward S. Cole0
Harry M. Meade0
Paul Ditullio0
Date of Patent
March 28, 2006
0Patent Application Number
101886580
Date Filed
July 2, 2002
0Patent Primary Examiner
Golden AI
Edits made to:
US Patent 7019193 Treatments using transgenic goat produced antithrombin III
Find more entities like US Patent 7019193 Treatments using transgenic goat produced antithrombin III
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.